Study of Blood and Tissue Biomarkers to Improve Diagnosis and Outcomes in Women with Endometriosis

What this Trial Is About

Endometriosis is a chronic, non-cancerous, estrogen-dependent condition where tissue similar to the lining inside the uterus grows outside it, affecting areas like the ovaries, intestines, or other pelvic and non-pelvic sites. It commonly causes pain and infertility and affects 7-10% of women worldwide. Diagnosis usually requires tissue removal and examination via laparoscopy. This study aims to investigate blood and tissue biomarkers to improve diagnosis, staging, and prediction of relapse and fertility outcomes, while also assessing quality of life after surgery for advanced disease stages. The study observes women aged 18 to 45 who undergo surgery for suspected endometriosis or other benign gynecological conditions without endometriosis. Participants are grouped by endometriosis severity or as controls without the disease. Blood biomarkers in plasma and serum are collected to evaluate their accuracy for diagnosis preoperatively and changes after surgery in severe cases. Quality of life and pregnancy outcomes are also monitored up to one year after surgery. Participants will have blood samples taken before surgery and again 3 to 6 months after surgery if they have severe endometriosis. Questionnaires assess quality of life before and after surgery for severe cases, and pregnancy status is followed for one year postoperatively. The study measures the sensitivity and specificity of blood biomarkers for detecting endometriosis and tracks changes over time. This observational study lasts from preoperative assessment through one year post-surgery, focusing on womens clinical outcomes and biomarker profiles.

Blood and Tissue Markers for Improving Diagnosis and Prognosis of Endometriosis. (ENDOBIO)